Invasive Ductal Carcinoma (IDC)
Invasive ductal carcinoma (IDC) is characterized by the uncontrolled growth and spread of malignant cells that have breached the walls of the milk ducts, allowing them to infiltrate the surrounding breast tissue. At Alfa Cytology, our team of experienced biologists work with you to develop invasive ductal carcinoma therapeutics.
Introduction to Invasive Ductal Carcinoma (IDC)
Invasive ductal carcinoma (IDC) is the most common form of breast cancer, accounting for approximately 80% of all breast cancer diagnoses. This aggressive subtype of breast cancer originates in the milk ducts and then invades the surrounding breast tissue. According to the latest epidemiological data, the incidence of invasive ductal carcinoma has remained relatively stable in recent years, with an estimated 180,000 new cases diagnosed annually in the United States alone. Increasing incidence of IDC across the globe due to factors such as aging population, changing lifestyles, and heredity has greatly contributed to the expansion of the breast cancer treatment market.
Ongoing Clinical Trials in Invasive Ductal Carcinoma (IDC)
Researchers are actively involved in several clinical trials exploring innovative approaches to the treatment of invasive ductal carcinoma. These trials are designed to evaluate the safety and efficacy of novel therapeutic agents, combination therapies, and advanced diagnostic techniques.
| NCT | Therapy | Therapeutics | Phase |
| NCT01953588 | Neoadjuvant Endocrine Therapy | Fulvestrant + Anastrozole | |
| NCT03947151 | Endocrine Therapy | Degarelix |
Our Services
As a leading preclinical contract research organization (CRO), Alfa Cytology has established a strong reputation for its expertise in invasive ductal carcinoma research. The company's multidisciplinary team of scientists and regulatory specialists collaborate seamlessly to provide comprehensive and tailored solutions for clients in the pharmaceutical and biotechnology industries.
Therapeutics Development
Animal Models of Invasive Ductal Carcinoma
|
|
| Optional Cell Lines: BT20, BT474, MCF-7, MDA-MB-435, SUM1315, ZR-75-1, Others | Optional Transgene: PyMT, SV40, Others |
Case Study
Establishment of a DMBA-Induced Breast Cancer Model and In Vivo Evaluation of Compound A
- Model Introduction
The DMBA-induced breast cancer model is a classic and reliable preclinical tool for studying hormone receptor-positive breast cancer. This chemical carcinogenesis model, established by administering DMBA (7,12-dimethylbenz[a]anthracene), reliably produces invasive ductal adenocarcinomas that mirror the most common form of human breast cancer. It provides a robust platform for evaluating the efficacy of novel chemotherapeutic and chemopreventive agents.
- Model Information
- Model: DMBA-Induced Breast Cancer Model
- Cancer Type: Hormone Receptor-Positive Breast Cancer (Invasive Ductal Adenocarcinoma)
- Host Mouse Strain: Female Sprague-Dawley Rats
- Age: 6-8 Weeks
- Induction Agent: DMBA (7,12-Dimethylbenz[a]anthracene)
- Induction Method: Single Intraperitoneal Injection
- Weight: 150-170 g
- Model Construction
The model was established by administering a single intraperitoneal injection of DMBA (25 mg/kg) to female Sprague-Dawley rats to initiate carcinogenesis. Tumor development was monitored through regular palpation, with palpable tumor formation typically confirmed within 4-5 weeks post-injection. Tumor volume was systematically measured using the standard formula: 0.5 × length × width2.
- In Vivo Efficacy Evaluation
This case employed the established DMBA-induced breast cancer rat model to systematically evaluate the therapeutic efficacy of compound A and its nanoemulsion formulation.
- Significant Tumor Growth Inhibition: Treatment with compound A and its nanoemulsion formulation resulted in potent, dose-dependent suppression of primary tumor growth compared to the DMBA control group, demonstrating strong anti-tumor activity.
- Enhanced Apoptotic Induction: Both compound A and the nanoemulsion significantly increased tumor cell apoptosis rates, confirming the activation of programmed cell death pathways as a key mechanism of anti-cancer activity.
Fig. 2 Effects of Compound A and its nanoemulsion on tumor growth before and after treatment. The data displays the mean ± standard deviation, with * p < 0.05, ** p < 0.001, and *** p < 0.0001 indicating statistical significance compared to the vehicle control group and DMBA-induced group. (Source: Alfa Cytology)
By collaborating with Alfa Cytology, clients gain access to a comprehensive suite of services tailored to the unique needs of invasive ductal carcinoma research and development. From preclinical study design and execution to data analysis, the company's team of experts is dedicated to empowering clients' efforts in bringing transformative invasive ductal carcinoma therapies to market. If you are interested in our service, please contact us.
Reference
- Trayes K. P., Cokenakes S. E. H. Breast Cancer Treatment. Am Fam Physician. 2021, 104(2): 171-178.